Receiving assistance from a drug corporation to afford an expensive prescription feels a lot like pharma benevolence. Here's why these programs are robbing us blind:
There is a simple and potentially cost-saving question patients may not know they can ask their pharmacists.
WASHINGTON, D.C. — “Don’t Get Fooled Again.” That’s the message from cancer patient and founder and president of Patients For Affordable Drugs David Mitchell to 50 Democratic members of the House. The members all signed on to a letter supporting drug corporations’ lobbying efforts to rollback Big Pharma’s contribution to Medicare that saves patients and taxpayers money.
WASHINGTON, DC — Seniors are filling fewer prescriptions for brand-named drugs, but they’re spending significantly more because list prices keep going up, according to a new government report. In response, David Mitchell, a cancer patient and founder of Patients For Affordable Drugs, issued the following statement.
In an attempt to encourage and improve transparency, the FDA released a list of more than 50 drug makers accused by generic drug corporations of stalling providing samples that would increase competition and lower prices.
“We have an incredibly powerful, incredibly productive research and development program being run by N.I.H.,” Ameet Sarpatwari, an instructor at Harvard Medical School, said. “Taxpayers put in money that is paying big dividends, and yet we pay higher prices for prescription drugs than any other country. In effect, we have taxpayers paying twice.”
Patients For Affordable Drugs Joins Cystic Fibrosis Patients to Demand That Vertex Lower Its Drug Prices
St. Louis — Patients For Affordable Drugs stood with Lora Moser, a cystic fibrosis patient unable to afford the medicines her family spent decades fundraising to develop, and launched a new campaign demanding that Vertex Pharmaceuticals lower the price of its life-extending drugs.
Moser and Patients For Affordable Drugs were represented Thursday at a meeting of the Institute For Clinical and Economic Review (ICER) by Juliana Keeping, mother to Eli, 5, who also has cystic fibrosis.
The problem is the price: 5 reasons the cystic fibrosis community and its allies must band together to speak out about our drug prices – right now.
But I live in fear that we won’t be able to afford his medication from Vertex. I live in fear that stock buybacks and CEO pay raises will come before lowering the price of Eli’s drugs. That’s why I decided to fight back. That’s why I’m calling on all shareholders and the cystic fibrosis community to demand Vertex use its windfall in corporate tax breaks to lower the price of Cystic Fibrosis drugs.